MARKET

JANX

JANX

Janux Therapeutics, Inc.
NASDAQ
16.51
+0.11
+0.67%
After Hours: 16.44 -0.07 -0.42% 19:46 12/05 EST
OPEN
16.40
PREV CLOSE
16.40
HIGH
16.54
LOW
16.00
VOLUME
2.14M
TURNOVER
--
52 WEEK HIGH
71.71
52 WEEK LOW
15.51
MARKET CAP
993.04M
P/E (TTM)
-9.8567
1D
5D
1M
3M
1Y
5Y
1D
LifeSci Capital Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks · 1d ago
What Moved Markets This Week
Seeking Alpha · 1d ago
Janux Therapeutics Chief Business Officer Andrew Hollman Meyer Reports Disposal of Common Shares
Reuters · 3d ago
Janux Therapeutics: Downgrading To "Hold" Rating After Latest Updated Phase 1 JANX007 mCRPC Data
Seeking Alpha · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Schrodinger (SDGR), Compass Therapeutics (CMPX)
TipRanks · 4d ago
Evercore ISI Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
TipRanks · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
Reuters · 4d ago
Gold Down Over 1%; Signet Shares Fall After Q3 Results
Benzinga · 4d ago
More
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Webull offers Janux Therapeutics Inc stock information, including NASDAQ: JANX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JANX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JANX stock methods without spending real money on the virtual paper trading platform.